Allakos (Allakos) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Allakos 3-Year Revenue Growth Rate?

Allakos's Revenue per Share for the three months ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Allakos's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Allakos's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allakos's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allakos's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Allakos's 3-Year Revenue Growth Rate falls into.

Allakos 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Allakos (NAS:ALLK) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Allakos 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Allakos's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Allakos (Allakos) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (NAS:ALLK) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

37Z:Germany

Address

825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070

Website

https://www.allakos.com

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Executives

Graham Neil Murray Hamilton	director	33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Everett Rand Sutherland	director	29 HARTWELL AVENUE, LEXINGTON MA 02421
Dolca Thomas	director	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Paul Edward Walker	director	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Daniel Janney	director	PO BOX 7414, JACKSON WY 83002
Amy L Ladd	director	INTUITIVE SURGICAL, INC, 1020 KIFER RD, SUNNYVALE CA 94086
Craig A. Paterson	officer: Chief Medical Officer	ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Margaret Nell Fitzgerald	officer: General Counsel and Secretary	ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Steven P James	director	C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Adam Tomasi	officer: COO, CFO and Secretary	ZS PHARMA, INC., 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Robert Alexander	director, officer: President and CEO	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Harlan Baird Radford	officer: Chief Financial Officer	C/O EBAY INC., 2145 HAMILTON AVENUE, SAN JOSE CA 95125
Rasmussen Henrik S Md	officer: Chief Medical Officer	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
John P Mckearn	director, 10 percent owner	5820 NANCY DRIVE, SAN DIEGO CA 92121
Peter A Hudson	10 percent owner	701 COOL SPRINGS BOULEVARD, FRANKLIN TN 37067